Literature DB >> 26410875

Cannabinoid 2 receptor activation reduces leukocyte adhesion and improves capillary perfusion in the iridial microvasculature during systemic inflammation.

J T Toguri1,2, R Moxsom1, A M Szczesniak1, J Zhou2,3, M E M Kelly1,2,4, C Lehmann1,2,3.   

Abstract

BACKGROUND: Leukocyte adhesion to the endothelium and decreased microvascular blood flow causing microcirculatory dysfunction are hallmarks of systemic inflammation. We studied the impact of cannabinoid receptor activation on the iridial microcirculation, which is accessible non-invasively in vivo, in systemic inflammation induced by endotoxin challenge.
METHODS: 40 Lewis rats were used in the experiments. Endotoxemia was induced by 2 mg/kg i.v. lipopolysaccharide (LPS). Cannabinoid receptors (CBRs) were stimulated by i.v. administration of WIN 55212-2 (WIN; 1 mg/kg). CB1R antagonist (AM281; 2.5 mg/kg i.v.) or CB2R antagonist (AM630; 2.5 mg/kg i.v.) treatment prior to WIN was applied to identify the anti-inflammatory effects underlying each CBR subtype. Leukocyte-endothelial interactions were examined in rat iridial microvas culature by intravital microscopy at baseline and 1 and 2 h post-LPS. Additionally, systemic (mean arterial pressure, heart rate) and local (laser Doppler flow) hemodynamic variables were measured prior to and during cannabinoid treatments.
RESULTS: Endotoxemia resulted in severe inflammation as shown by significantly increased numbers of adherent leukocytes at 1 and 2 h observation time post-LPS challenge and decreased microcirculatory blood flow at 2 h within the iridial microcirculation. WIN treatment significantly reduced leukocyte adhesion in iridial microvessels with a diameter greater and less than 25 μm during endotoxemia (p <  0.05). Pre-treatment of animals by CB1R antagonist, AM281, did not affect WIN effects on LPS-induced leukocyte adhesion. When pre-treated with the CB2R antagonist, AM630, a reversal of the WIN-induced reduction in leukocyte adhesion was noticed in vessels with a diameter of less than 25 μm (p <  0.05). Cannabinoid treatment significantly increased the local iridial microcirculatory blood flow 2 hours after systemic LPS administration (p <  0.05).
CONCLUSIONS: Systemic administration of the CBR agonist, WIN, decreased leukocyte-adhesion and improved iridial microvascular blood flow. This effect is most likely mediated by CB2R activation. Our findings indicate that the iris microvasculature can serve as a model to study the microcirculation during systemic inflammation and help to identify potential therapies to treat microcirculatory dysfunction in diseases such as sepsis.

Entities:  

Keywords:  Endotoxemia; WIN 55212-2; cannabinoid receptor; microcirculation

Mesh:

Substances:

Year:  2015        PMID: 26410875     DOI: 10.3233/CH-151996

Source DB:  PubMed          Journal:  Clin Hemorheol Microcirc        ISSN: 1386-0291            Impact factor:   2.375


  12 in total

Review 1.  Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies.

Authors:  Vamsi Reddy; Dayton Grogan; Meenakshi Ahluwalia; Évila Lopes Salles; Pankaj Ahluwalia; Hesam Khodadadi; Katelyn Alverson; Andy Nguyen; Srikrishnan P Raju; Pankaj Gaur; Molly Braun; Fernando L Vale; Vincenzo Costigliola; Krishnan Dhandapani; Babak Baban; Kumar Vaibhav
Journal:  EPMA J       Date:  2020-04-15       Impact factor: 6.543

2.  RCP induces Slug expression and cancer cell invasion by stabilizing β1 integrin.

Authors:  M H Hwang; K H Cho; K J Jeong; Y-Y Park; J M Kim; S-L Yu; C G Park; G B Mills; H Y Lee
Journal:  Oncogene       Date:  2016-08-15       Impact factor: 9.867

3.  β-Caryophyllene, A Natural Dietary CB2 Receptor Selective Cannabinoid can be a Candidate to Target the Trinity of Infection, Immunity, and Inflammation in COVID-19.

Authors:  Niraj Kumar Jha; Charu Sharma; Hebaallah Mamdouh Hashiesh; Seenipandi Arunachalam; Mf Nagoor Meeran; Hayate Javed; Chandragouda R Patil; Sameer N Goyal; Shreesh Ojha
Journal:  Front Pharmacol       Date:  2021-05-14       Impact factor: 5.810

Review 4.  Potential for endocannabinoid system modulation in ocular pain and inflammation: filling the gaps in current pharmacological options.

Authors:  J Daniel Lafreniere; Melanie E M Kelly
Journal:  Neuronal Signal       Date:  2018-11-02

Review 5.  Neuroprotection by (endo)Cannabinoids in Glaucoma and Retinal Neurodegenerative Diseases.

Authors:  Cinzia Rapino; Daniel Tortolani; Lucia Scipioni; Mauro Maccarrone
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

Review 6.  Can Echinacea be a potential candidate to target immunity, inflammation, and infection - The trinity of coronavirus disease 2019.

Authors:  M F Nagoor Meeran; Hayate Javed; Charu Sharma; Sameer N Goyal; Sanjay Kumar; Niraj Kumar Jha; Shreesh Ojha
Journal:  Heliyon       Date:  2021-02-08

Review 7.  Real-Time Imaging of Immune Modulation by Cannabinoids Using Intravital Fluorescence Microscopy.

Authors:  Juan Zhou; Kiyana Kamali; J Daniel Lafreniere; Christian Lehmann
Journal:  Cannabis Cannabinoid Res       Date:  2021-05-27

Review 8.  Turning Down the Thermostat: Modulating the Endocannabinoid System in Ocular Inflammation and Pain.

Authors:  James T Toguri; Meggie Caldwell; Melanie E M Kelly
Journal:  Front Pharmacol       Date:  2016-09-15       Impact factor: 5.810

9.  Cannabinoid Receptor 2 Modulates Neutrophil Recruitment in a Murine Model of Endotoxemia.

Authors:  Theodore S Kapellos; Carlota Recio; David R Greaves; Asif J Iqbal
Journal:  Mediators Inflamm       Date:  2017-08-09       Impact factor: 4.711

10.  The Cannabinoids Δ8THC, CBD, and HU-308 Act via Distinct Receptors to Reduce Corneal Pain and Inflammation.

Authors:  Dinesh Thapa; Elizabeth A Cairns; Anna-Maria Szczesniak; James T Toguri; Meggie D Caldwell; Melanie E M Kelly
Journal:  Cannabis Cannabinoid Res       Date:  2018-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.